HHS Contracts with BioCryst to Develop New Ebola Drug

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded approximately $12 million to BioCryst Pharmaceuticals for the advanced development of a promising experimental drug for Ebola.

Pricing and Policies for Biosimilars Are Announced

The Centers for Medicare and Medicaid Services (CMS) plans to begin paying for biosimilars through its Part B,Part D and state coverage policies by this summer, according to a question-and-answer document released in April.